

CNCR

Range Cancer Therapeutics ETF

Analyst Report

CNCR tracks an equal-weighted index of companies currently developing oncology drugs or selling cancer therapeutic products.

ESG Themes and Scores

4.46/10

ESG Rate

14.11%

Global Percentile

6.25%

Peer Percentile

Performance Data

	CNCR	ETF Database Category Average	Factset Segment Average
1 Month	-3.99%	4.51%	4.77%
3 Month	-17.48%	-0.36%	-1.63%
YTD Return	1.62%	6.63%	8.39%
1 Year Return	-16.49%	5.24%	-0.25%
3 Year Return	-12.61%	-0.15%	-5.28%
5 Year Return	-9.24%	2.01%	-1.16%

Top 5 Holdings

Symbol	Holding	% Assets
DNA	Ginkgo Bioworks Holdings, Inc. Class A	4.13%
RXR	Recursion Pharmaceuticals, Inc. Class A	3.78%
CMPX	Compass Therapeutics, Inc.	3.11%
GNLX	Genelux Corp.	2.60%
PGEN	Precigen Inc	2.35%

Vitals

Issuer	Exchange Traded Concepts
Brand	Range
Structure	ETF
Expense Ratio	0.79%
Inception	Oct 13, 2015
Index Tracked	Range Oncology Therapeutics Index

ETF Database Themes

Category	Health & Biotech Equities
Asset Class	Equity
Asset Class Size	Multi-Cap
Asset Class Style	Blend
Region (General)	Developed Markets
Region (Specific)	Broad

FactSet Classifications

Segment	Equity: Global Pharma, Biotech & Life Sciences
Category	Sector
Focus	Health Care
Niche	Pharma, Biotech & Life Sciences
Strategy	Equal
Weighting	Equal

